Chester County News and Community Website
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) reported third quarter 2025 financial results and highlighted steady momentum across its antiviral programs, including Phase 2 progress for its COVID candidate …
Traws Pharma Pushes Ahead on COVID and Flu Antivirals as Costs Fall and Pipeline Advances Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has begun dosing participants in a Phase 2 clinical trial evaluating ratutrelvir, a ritonavir-free antiviral therapy for newly diagnosed COVID-19 patients. The …
Traws Pharma Begins Phase 2 Trial of Ritonavir-Free COVID-19 Treatment Ratutrelvir Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) announced the appointment of John Leaman, MD, to its board of directors as an independent director, further strengthening its leadership as the …
Traws Pharma Appoints Dr. John Leaman to Board, Confirms CEO and CFO Roles Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) announced it has received approval from the Human Research Ethics Committee (HREC) to begin Phase 2 clinical trials of ratutrelvir, a ritonavir-free …
Traws Pharma Receives Approval to Launch Phase 2 Trials for Ritonavir-Free COVID Treatment Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) posted second-quarter 2025 results and outlined strategic progress on its antiviral drug pipeline, with a focus on COVID-19 and influenza treatments designed …
Traws Pharma Reports Q2 Results, Advances COVID-19 and Influenza Antiviral Programs Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has unveiled key clinical efficacy data for rigosertib, showcasing its potential as a treatment for squamous cell carcinoma (SCC) associated with recessive …
Traws Pharma Announces Promising Clinical Data for Rigosertib in Rare Cancer Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) announced receipt of key guidance from the U.S. Food and Drug Administration (FDA) regarding the development of its investigational antiviral, tivoxavir marboxil …
Traws Pharma Receives FDA Feedback on Flu Drug Development Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has reported its first-quarter financial results and provided updates on its investigational antiviral programs, underscoring advancements toward regulatory approval and potential breakthroughs …
Traws Pharma Highlights Q1 2025 Financial Progress and Antiviral Developments Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has released its financial results for the year ending December 31, 2024, alongside significant updates to its investigational programs. The company has made …
Traws Pharma Reports 2024 Financial Results and Advances Bird Flu and COVID Programs Read More NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has announced the retirement of Werner Cautreels, PhD, from his role as Chief Executive Officer, effective March 31, 2025. This leadership transition will …
Traws Pharma Announces CEO Transition as Werner Cautreels Retires Read More